|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar
|
|
4
|
Assaraf YG: Molecular basis of antifolate
resistance. Cancer Metastasis Rev. 26:153–181. 2007. View Article : Google Scholar
|
|
5
|
Furrukh M, Al-Moundhri M, Zahid KF, Kumar
S and Burney I: Customised, individualised treatment of metastatic
non-small-cell lung carcinoma (NSCLC). Sultan Qaboos Univ Med J.
13:202–217. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longo-Sorbello GS, Chen B, Budak-Alpdogan
T and Bertino JR: Role of pemetrexed in non-small cell lung cancer.
Cancer Invest. 25:59–66. 2007. View Article : Google Scholar
|
|
7
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esteban E, Casillas M and Cassinello A:
Pemetrexed in first-line treatment of non-small cell lung cancer.
Cancer Treat Rev. 35:364–373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang D, Ochi N, Takigawa N, et al:
Establishment of pemetrexed-resistant non-small cell lung cancer
cell lines. Cancer Lett. 309:228–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu SG, Yang CH, Yu CJ, et al: Good
response to pemetrexed in patients of lung adenocarcinoma with
epidermal growth factor receptor (EGFR) mutations. Lung
Cancer. 72:333–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Benavente S, Huang S, Armstrong EA, et al:
Establishment and characterization of a model of acquired
resistance to epidermal growth factor receptor targeting agents in
human cancer cells. Clin Cancer Res. 15:1585–1592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giltnane JM, Moeder CB, Camp RL and Rimm
DL: Quantitative multiplexed analysis of ErbB family coexpression
for primary breast cancer prognosis in a large retrospective
cohort. Cancer. 115:2400–2409. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma SV and Settleman J: ErbBs in lung
cancer. Exp Cell Res. 315:557–571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashi M, Inokuchi M, Takagi Y, et al:
High expression of HER3 is associated with a decreased survival in
gastric cancer. Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mimeault M, Hauke R and Batra SK: Recent
advances on the molecular mechanisms involved in the drug
resistance of cancer cells and novel targeting therapies. Clin
Pharmacol Ther. 83:673–691. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmidt M and Lichtner RB: EGF receptor
targeting in therapy-resistant human tumors. Drug Resist Updat.
5:11–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Desbois-Mouthon C: The HER3/ErbB3
receptor: a promising target in cancer drug therapy. Gastroenterol
Clin Biol. 34:255–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blivet-Van Eggelpoël MJ, Chettouh H,
Fartoux L, et al: Epidermal growth factor receptor and HER-3
restrict cell response to sorafenib in hepatocellular carcinoma
cells. J Hepatol. 57:108–115. 2012.PubMed/NCBI
|
|
20
|
Lu S, Zheng W, Ji L, et al: Synthesis,
characterization, screening and docking analysis of
4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. Eur
J Med Chem. 61:84–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Y, Ling XL, Li SW, Li XQ and Yan B:
Establishment of a human hepatoma multidrug resistant cell line in
vitro. World J Gastroenterol. 16:2291–2297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikari A, Sato T, Watanabe R, Yamazaki Y
and Sugatani J: Increase in claudin-2 expression by an
EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells.
Biochim Biophys Acta. 1823:1110–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaszubiak A, Holm PS and Lage H:
Overcoming the classical multidrug resistance phenotype by
adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
Int J Oncol. 31:419–430. 2007.PubMed/NCBI
|
|
24
|
Amati P and Lago C: Sensitivity to
amphotericin B of in vitro established cell lines. Nature.
247:466–469. 1974. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Snow K and Judd W: Characterisation of
adriamycin- and amsacrine-resistant human leukaemic T cell lines.
Br J Cancer. 63:17–28. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu X, Errington J, Curtin NJ, Lunec J and
Newell DR: The impact of p53 status on cellular sensitivity
to antifolate drugs. Clin Cancer Res. 7:2114–2123. 2001.
|
|
27
|
Hsu HF, Huang KH, Lu KJ, et al:
Typhonium blumei extract inhibits proliferation of human
lung adenocarcinoma A549 cells via induction of cell cycle arrest
and apoptosis. J Ethnopharmacol. 135:492–500. 2011. View Article : Google Scholar
|
|
28
|
Heinemann L, Simpson GR, Annels NE, et al:
The effect of cell cycle synchronization on tumor sensitivity to
reovirus oncolysis. Mol Ther. 18:2085–2093. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanauske AR, Eismann U, Oberschmidt O, et
al: In vitro chemosensitivity of freshly explanted tumor cells to
pemetrexed is correlated with target gene expression. Invest New
Drugs. 25:417–423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ozasa H, Oguri T, Uemura T, et al:
Significance of thymidylate synthase for resistance to pemetrexed
in lung cancer. Cancer Sci. 101:161–166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu MF, Hsiao YM, Huang CF, et al: Genetic
determinants of pemetrexed responsiveness and nonresponsiveness in
non-small cell lung cancer cells. J Thorac Oncol. 5:1143–1151.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sebastian S, Settleman J, Reshkin SJ,
Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting
EGFR signalling in cancer: from expression to turnover. Biochim
Biophys Acta. 1766:120–139. 2006.PubMed/NCBI
|
|
33
|
Durmuş Tekir S, Yalçin Arga K and Ulgen
KO: Drug targets for tumorigenesis: insights from structural
analysis of EGFR signaling network. J Biomed Inform. 42:228–236.
2009.PubMed/NCBI
|
|
34
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
|
|
35
|
Kosaka T, Yatabe Y, Endoh H, et al:
Analysis of epidermal growth factor receptor gene mutation in
patients with non-small cell lung cancer and acquired resistance to
gefitinib. Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto H, Toyooka S and Mitsudomi T:
Impact of EGFR mutation analysis in non-small cell lung
cancer. Lung Cancer. 63:315–321. 2009.
|
|
37
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grøvdal LM, Kim J, Holst MR, Knudsen SL,
Grandal MV and van Deurs B: EGF receptor inhibitors increase ErbB3
mRNA and protein levels in breast cancer cells. Cell Signal.
24:296–301. 2012.PubMed/NCBI
|
|
39
|
Kawano O, Sasaki H, Endo K, et al: ErbB3
mRNA expression correlated with specific clinicopathologic features
of Japanese lung cancers. J Surg Res. 146:43–48. 2008. View Article : Google Scholar : PubMed/NCBI
|
